1. Abel R, Leopold IH: Ocular Diseases, in Speight TM (ed): Avery's Drug Treatment. Principles and Practice of Clinical Pharmacology and Therapeutics. Auckland, Adis; 1987:387-417.

2. Abuekteish F, Kirkpatrick JNP, Russell G: Posterior subcapsular cataract and inhaled corticosteroid therapy. Thorax 1995;50:674-676.

3. Acott TS, Kingsley PD, Samples JR, Van Buskirk EM: Human trabecular meshwork organ culture: morphology and glycosaminoglycan synthesis. Invest Ophthalmol Vis Sci 1988;29:90-100.

4. Adhikary HP, Sells RA, Basu PK: Ocular complications of systemic steroid after renal transplantation and their association with HLA. Br J Ophthalmol 1982;66:290-291.

5. Agertoft L, Larsen FE, Pedersen S: Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998;12:130-135.

6. Alfano JE: Changes in the intraocular pressure associated with systemic steroid therapy. Am J Ophthalmol 1963;56:245-247.

7. Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B: Steroid aerosols and cataract formation. BMJ 1989;299:432-433.

8. Anderson EI, Wright DD, Spector A: The state of sulfhydryl groups in normal and cataractous human lens proteins. II. Cortical and nuclear regions. Exp Eye Res 1979;29:233-243.

9. Andrade SE, Platt R, Gottlieb LK, Saperia GM, Walker AM: Discontinuations of antihyperlipidemic drug therapy: assessment by means of automated databases. Pharmacoepidemiol Drug Saf 1996;5:113-120.

10. Armaly MF: Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963;70:492-499.

11. Armaly MF: Effect of corticosteroids on intraocular pressure and fluid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-491.

12. Armaly MF: Statistical attributes of the steroid hypertension response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol Vis Sci 1965;4:187-197.

13. Armaly MF: The heritable nature of dexamethasone-induced ocular hypertension. Arch Ophthalmol 1966;75:32-35.

14. Armaly MF: Characteristics of the steroid effect on intraocular pressure and aqueous dynamics, in Paterson G, Miller SJH, Paterson GD (eds): Drug Mechanisms in Glaucoma. London, J.&A.Churchill LTD; 1966:191-228.

15. Armaly MF: Inheritance of dexamethasone hypertension and glaucoma. Arch Ophthalmol 1967;77:747-751.

16. Armaly MF: Genetic factors related to glaucoma. Ann N Y Acad Sci 1968;151:861-875.

17. Armaly MF: Corticosteroid Glaucoma, in Cairns JE (ed): Glaucoma. London, Grune&Stratton; 1986:697-710.

18. Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, Walker A: Neuroleptic drug exposure and treatment of parkinsonism in the elderly: A case-control study. Am J Med 1995;99:48-54.

19. Bakke OM, Wardell WM, Lasagna L: Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety. Clin Pharmacol Ther 1984;35:559-567.

20. Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17:245-261.

21. Barandun J: Inhalationstherapie bei chronisch obstruktiven bronchialen Erkrankungen. Schweiz Med Wochenschr 1996;126:1693-1703.

22. Barnes NC: Safety of high-dose inhaled corticosteroids. Resp Med 1993;87 (Suppl.A):27-31.

23. Barnes PJ: Inhaled glucocorticoids for asthma. N Engl J Med 1995;332:868-875.

24. Becker B: Intraocular pressure response to topical corticosteroids. Invest Ophthalmol Vis Sci 1965;4:198-205.

25. Becker B, Hahn KA: Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964;57:543-551.

26. Becker B, Mills DW: Corticosteroids and intraocular pressure. Arch Ophthalmol 1963;70:500-507.

27. Bengtsson B: Manifest glaucoma in the aged I: occurrence nine years after a population survey. Acta Op h thalmol 1981;59:321-331.

28. Bernstein HN, Schwartz B: Effects of long term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol 1962;68:742-754.

29. Bettman JW, Fung WE, Noyes PO: Potentiating action of prednisolone on galactose cataracts in rats. Invest Ophthalmol 1964;3:678-679.

30. Bettman JW, Noyes PO, DeBaskey R: The potentiating action of steroids in cataractogenesis. Invest Op h thalmol 1964;3:459

31. Bihari M, Grossman BJ: Posterior subcapsular cataracts related to long-term corticosteroid treatment in children. Amer J Dis Child 1968;116:604-608.

32. Bill A: The drainage of aqueous humor. Invest Ophthalmol Vis Sci 1975;14:1

33. Bisgaard H, Damkjaer Nielsen M, Andersen B, Foged N, Fuglsang G, Host A, Leth C, Pedersen M, Pelck I: Adrenal function in children with bronchial asthma treated with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol 1988;81:1088-1095.

34. Black RL, Oglesby RB, von Sallmann L, Bunim JJ: Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960;174:166-171.

35. Blais L, Ernst P, Suissa S: Confounding by indication and channeling over time: the risks of beta-2-agonists. Am J Epidemiol 1996;144:1161-1169.

36. Bochow TW, West SK, Azar A, Munoz B, Sommer A, Taylor HR: Ultraviolet light exposure and risk of posterior subcapsular cataracts. Arch Ophthalmol 1989;107:369-372.

37. Bonting SL, Caravaggio LL, Hawkins NM: Studies on sodium-potassium activated adenosine triphosphatase VI, its role in cation transport in the lens of cat, calf and rabbit. Arch Biochem 1963;101:47

38. Braver DA, Richards RD, Good TA: Posterior subcapsular cataracts in steroid treated children. Arch Op h thalmol 1967;77:161-162.

39. Bresnick EH, Dalman FC, Sanchez ER, Pratt WB: Evidence that the 90-kDa heat schock protein is necessary for the steroid binding conformation of the L cell glucocorticoid receptor. J Biol Chem 1989;264:4992-4997.

40. British Thoracic Society: Guidelines for management of asthma in adults: I-chronic persistent asthma. BMJ 1990;301:651-653.

41. British Thoracic Society and others: Guidelines for the management of asthma: a summary. BMJ 1993;306:776-782.

42. Brogden RN, Heel RC, Speight TM, Avery GS: Beclomethasone diproprionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs 1992;28:99-126.

43. Brogden RN, McTavish D: Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407.

44. Brogden RN, Pinder RM, Sawyer PR, Speight TM, Avery GS: Beclomethasone dipropionate inhaler: A review of its pharmacology, therapeutic value and adverse effects. I: Asthma. Drugs 1975;10:166-210.

45. Brown PH, Blundell G, Greening AP, Crompton GK: Screening for hypothalamic-pituitary-adrenal axis suppression in asthmatics taking high dose inhaled corticosteroids. Respir Med 1991;85:511-516.

46. Brown PH, Blundell G, Greening AP, Crompton GK: Hypothalamic-pituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med 1991;85:501-510.

47. Brubaker RF, Halpin JA: Open-angle glaucoma associated with topical administration of flurandrenolide to the eye. Mayo Clin Proc 1975;50:322-326.

48. Bryson HM, Faulds D: Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs 1992;43:760-775.

49. Bucala R, Fishman J, Cerami A: Formation of covalent adducts between cortisol and 16-alpha-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci 1982;79:3320-3324.

50. Bucala R, Manabe S, Urban RC, Cerami A: Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies. Exp Eye Res 1985;41:353-363.

51. Bucala R, Manabe S, Urban RC, Cerami A: Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res 1985;40:853-863.

52. Burde RM, Becker B: Corticosteroid-induced glaucoma and cataracts in contact lens wearers. JAMA 1970;213:2075-2077.

53. Butcher JM, Austin M, McGalliard J, Bourke RD: Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ 1994;309:43

54. Buttgereit F, Dimmeler S, Neugebauer E, Burmester GR: Wirkungsmechanismen der hochdosierten Glucocorticoidtherapie. DMW 1996;121:248-252.

55. Carlsson B, Sjöstrand J: Increased incidence of cataract extractions in women above 70 years of age. Acta Ophthalmologica Scandinavica 1996;74:64-68.

56. Carson JL, Strom BL: Medicaid databases, in Strom BL (ed): Pharmacoepidemiology. Chichester, John Wiley and Sons; 1995:199-216.

57. Clark DJ, Lipworth BJ: Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997;52:55-58.

58. Clark WG, Brater DC, Johnson AR: Pharmacokinetic characteristics of drugs, in Clark WG, Brater DC, Johnson AR (eds): Goth's Medical Pharmacology. St.Louis, C.V.Mosby; 1992:773-792.

59. Clissold SP, Heel RC: Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984;28:485-518.

60. Collet JP, Boivin JF, Spitzer WO: Bias and confounding in pharmacoepidemiology, in Strom BL (ed): Pha r macoepidemiology. Chichester, J.Wiley&Sons; 1994:609-627.

61. Costagliola C, Iuliano G, Menzione M, Apponi-Battini G, Auricchio G: Effect of topical glucocorticoid administration on the protein and nonprotein sulfhydryl groups of the rabbit lens. Ophthalmic Res 1987;19:351-356.

62. Cotlier E, Becker B: Topical corticosteroids and galactose cataracts. Invest Ophthalmol 1965;4:806-814.

63. Covell LL: Glaucoma induced by systemic steroid therapy. Am J Ophthalmol 1958;45:108-109.

64. Cremer-Bartels G, Hockwin O, Ganter K, Werry H: Additionskatarakt nach Corticosteroidapplikation bei Galaktose-gefütterten Ratten. Ber Dtsch Ophthal Ges 1968;69:436-439.

65. Cumming RG, Mitchell P, Leeder SR: Use of inhaled corticosteroids and the risk of cataracts. New Engl J Med 1997;337:8-14.

66. Cumming RG, Mitchell P, Leeder SR: Inhaled Corticosteroids and the Risk of Cataract (Reply). N Engl J Med 1997;337:1555

67. Danyluk AW, Paton D: Diagnosis and management of glaucoma. Clin Symp 1991;43:2-32.

68. Das SN, Hitchings RA: Steroid glaucoma. Trans Ophthalmol Soc UK 1971;91:749-756.

69. Derendorf H: Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997;91 (Suppl. A):22-28.

70. Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998;101:S440-S446.

71. Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, Erdman M: Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-305.

72. Dickerson JE, Steely HT, Englisch-Wright SL, Clark AF: The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells. Exp Eye Res 1998;66:731-738.

73. Dickerson JEJ, Dotzel E, Clark AF: Steroid-induced cataract: new perspective from in vitro and lens culture studies. Exp Eye Res 1997;65:507-516.

74. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT: The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994;101:1851-1855.

75. Draeger J: Der Einfluss lokaler Steroidgaben auf den Augeninnendruck. Klin Monatsbl Augenheilkd 1965;147:386-397.

76. Dreyer EB: Inhaled steroid use and glaucoma. N Engl J Med 1993;329:1822

77. Edsbäcker S, Andersson KE, Ryrfeldt A: Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 1985;29:477-481.

78. Efthimiou J, Barnes PJ: Effect of inhaled corticosteroids on bones and growth. Eur Respir J 1998;11:1167-1177.

79. Engelbrecht-Schnur S, Siegner A, Prehm P, Lütjen-Drecoll E: Dexamethasone treatment decreases hyaluronan-formation by primate trabecular meshwork cells in vitro. Exp Eye Res 1997;64:539-543.

80. Esch B, Paeschke N, Christ W, Kreutz G: Dokumentation und Bewertung von Arzneimittelnebenwirkungen am Beispiel des Ofloxacins. Infection 1991;19 (Suppl. 1):S9-S12.

81. Faich GA: Adverse-drug-reaction monitoring. N Engl J Med 1986;314:1589-1592.

82. Faich GA: US adverse drug reaction surveillance 1989-1994. Pharmacoepidemiol Drug Saf 1996;5:393-398.

83. Farmer R: General Practice Databases in the United Kingdom and their use in pharmacoepidemiology, in Lewis MA, Meyer R, Döpfmer S, Guggenmoos-Holzmann I (eds): Rapid Response Unit. Möglichkeiten und Bedarf der Pharmakoepidemiologie in Deutschland. Berlin, 1996:21-26.

84. Fauss DJ, Bloom E, Lui GM, Kurtz RM, Polansky JR: Glucocorticoid (GC) effects on HTM cells: Biochemical approaches and growth factor responses, in Lütjen-Drecoll E, Rohen JW (eds): Basic Aspects of Gla u coma Research III. Stuttgart, Schattauer; 1993:319-330.

85. Fisher RF: The Lens.Pathology of the Crystalline Lens, in Miller S (ed): Clinical Ophthalmology. London, Wright; 1988:275-281.

86. Forman AR, Loreto JA, Tina LU: Reversibility of corticosteroid-associated cataracts in children with the nephrotic syndrome. Am J Ophthalmol 1977;84:75-78.

87. Fournier C, Milot JA, Clermont M-J, O'Regan S: The concept of corticosteroid cataractogenic factor revisited. Can J Ophthalmol 1990;25:345-347.

88. Francois J: Cortisone et tension oculaire. Ann Oculist 1954;187:805-816.

89. Francois J: The importance of the mucopolysaccharides in intraocular pressure regulation. Invest Ophthalmol Vis Sci 1975;14:173

90. Francois J: Corticosteroid glaucoma. Ophthalmologica 1984;188:76-81.

91. Francois J, Benozzi G, Victoria-Troncosi V, Bohyn W: Ultrastructural and morphometric study of corticosteroid glaucoma in rabbits. Ophthalmic Res 1984;16:168

92. Francois J, Heintz-de Bree CH, Tripathi RC: The cortisone test and the heredity of primary open-angle glaucoma. Am J Ophthalmol 1966;62:844-852.

93. Fraunfelder FT, Meyer SM: Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Ophthalmol 1990;109:489-490.

94. Frenkel M: Blindness due to steroid induced glaucoma. IMJ - Illinois Medical Journal 1969;135:160-163.

95. Friedman GD: Kaiser Permanente Medical Care Program: Northern California and other regions, in Strom BL (ed): Pharmacoepidemiology. Chichester, John Wiley and Sons; 1995:187-197.

96. Garbe E, Müller-Oerlinghausen B: Datenbanken im Ausland für die Arzneimittelforschung nach der Zulassung. Ein Modell auch für Deutschland? Deutsches Ärzteblatt 1998;49:3138-3143.

97. Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM: Functional domains of the human glucocorticoid receptor. Cell 1986;46:645-652.

98. Giles CM, Mason GL, Duff IF, McLean JA: The association of cataract formation and systemic corticosteroid therapy. JAMA 1962;182:719-722.

99. Godel V, Feiler-Ofry V, Stein R: Systemic steroids and ocular fluid dynamics. I. Analysis of the sample as a whole. Influence of dosage and duration of therapy. Acta Ophthalmol 1972;50:655-663.

100. Goldberg S, Algur N, Levi M, Brukheimer E, Hirsch HJ, Branski D, Kerem E: Adrenal suppression among asthmatic children receiving chronic therapy with inhaled corticosteroid with and without spacer device. Ann Allgergy Asthma Immunol 1996;76:234-238.

101. Goldmann H: Cortisone glaucoma. Arch Ophthalmol 1962;68:621-626.

102. Gordon AC, McDonald CF, Thomson SA, Frame MH, Pottage A, Crompton GK: Dose of inhaled budesonide required to produce clincal suppression of plasma cortisol. Eur J Respir Dis 1987;71:10-14.

103. Gordon DM, Kammerer WH, Freyberg RH: Examination for posterior subcapsular cataracts. A preliminary report of results in forty-five rheumatoid patients treated with corticosteroids. JAMA 1961;175:127-129.

104. Grant WM: Ocular complications of drugs. Glaucoma. JAMA 1969;207:2089-2091.

105. Grehn F, Mackensen G: Die Glaukome, Stuttgart, W.Kohlhammer; 1993:

106. Griffin JP: Survey of the spontaneous adverse drug reaction schemes in fifteen countries. Br J Clin Pha r macol 1986;22 (Suppl. 1):83S-100S.

107. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993;118:273-278.

108. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154:97-101.

109. Hajek AS, Sossi N, Sossi G, Palmberg P: Dexamethasone phosphate increases the accumulation of collagen in the cell layer of cultured human trabecular endothelial cells. Invest Ophthalmol Vis Sci 1983;24:136

110. Hallas J, Hansen CG: Individual utilisation of anti-asthma medication by young adults: a prescription database analysis. J Intern Med 1993;234:65-70.

111. Hankinson SE, Seddon JM, Colditz GA, Stampfer MJ, Rosner B, Speizer FE, Willett WC: A prospective study of aspirin use and cataract extraction in women. Arch Ophthalmol 1993;111:503-508.

112. Hankinson SE, Willett WC, Golditz GA, Seddon JM, Rosner B, Speizer FE, Stampfer MJ. A prospective study of cigarette smoking and risk of cataract surgery in women. JAMA 1992;268:994-998.

113. Hardie I, Hilton A, Dyer J, Rumbach O: Ocular complications in renal transplant recipients. Transplant Proceed 1992;24:177

114. Harding JJ: Free and protein-bound glutathione in normal and cataractous human lenses. Biochem J 1970;117:957-960.

115. Harding JJ, Egerton M, van Heyningen R, Harding RS: Diabetes, glaucoma, sex, and cataract: analysis of combined data from two case-control studies. Br J Ophthalmol 1993;77:2-6.

116. Harris JL: Glaucoma associated with steroid therapy and atopic dermatitis. Am J Ophthalmol 1960;49:351-353.

117. Havre DC: Cataracts in children on long-term corticosteroid therapy. Arch Ophthalmol 1965;73:818-821.

118. Heinemann LAJ, DoMinh T, Guggenmoos-Holzmann I, Thiel C, Garbe E: Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997;56:275-284.

119. Heinemann LAJ, Garbe E: Third generation oral contraceptives and the risk of venous thromboembolism. Middle East Fert Soc J 1998;3:29-34.

120. Heinemann LAJ, Lewis MA, Assmann A, Gravens L, Guggenmoos-Holzmann I: Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives? Pharmacoepidemiol Drug Saf 1996;5:285-294.

121. Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-881.

122. Hernandez MR, Weinstein BI, Dunn MW, Gordon GG, Southren AL: The effect of dexamethasone on the synthesis of collagen in normal human trabecular meshwork explants. Invest Ophthalmol Vis Sci 1985;26:1784-1788.

123. Hernandez MR, Weinstein BI, Schwartz J, Ritch R, Gordon GG, Southren AL: Human trabecular meshwork cells in culture: morphology and extracellular matrix components. Invest Ophthalmol Vis Sci 1987;28:1655-1660.

124. Hernandez MR, Wenk EJ, Weinstein BI, Abumohor P, Podos SM, Dunn MW, Southren AL: Glucocorticoid target cells in human outflow pathway: autopsy and surgical specimens. Invest Ophthalmol Vis Sci 1983;24:1612-1616.

125. Hodapp EA, Kass MA: Corticosteroid-induced glaucoma, in Rich R, Shields MB (eds): The secondary Glaucomas. St.Louis, CV. Mosby Comp. 1982:258-265.

126. Hodge WG, Whitcher JP, Satariano W: Risk factors for age-related cataracts. Epidemiol Rev 1995;17:336-346.

127. Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM: Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985;318:635-641.

128. Hollows FC, Graham PA: Intraocular pressure, glaucoma and glaucoma suspects in a defined population. Br J Ophthalmol 1966;50:570-586.

129. Isaac NE, Walker AM, Jick H, Gorman M: Exposure to phenothiazine drugs and risk of cataract. Arch Op h thalmol 1991;109:256-260.

130. Jaanus SD, Bartlett JD, Hiett JA: Ocular effects of systemic drugs, in Bartlett JD, Jaanus SD (eds): Clinical Ocular Pharmacology. Boston, Butterworth-Heinemann; 1995:957-1006.

131. Jick H, Brandt DE: Allopurinol and cataracts. Am J Ophthalmol 1984;98:355-358.

132. Johnson D, Gottanka J, Flügel C, Hoffmann F, Ryusuke F, Lütjen-Drecoll E: Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids. Arch Ophthalmol 1997;115:375-383.

133. Johnson DH, Bradley JM, Acott TS, Fauss DJ, Polansky JR: The effect of steroids on human trabecular meshwork in perfusion organ culture (abstract). Invest Ophthalmol Vis Sci 1989;30 (suppl.):223

134. Johnson DH, Bradley JMB, Acott TS: The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci 1990;31:2568-2571.

135. Joseph KS: The evolution of clinical practice and time trends in drug effects. J Clin Epidemiol 1994;47:593-598.

136. Kahn HA, Leibowitz HM, Ganley JP, et al: The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977;106:17-32.

137. Kahn HA, Milton RC: Revised Framingham eye study prevalence of glaucoma and diabetic retinopathy. Am J Epidemiol 1980;111:769-776.

138. Kahn HA, Milton RC: Alternative definitions of open-angle glaucoma. Effect on prevalence and associations in the Framingham eye study. Arch Ophthalmol 1980;98:2172-2177.

139. Kanski JJ: The Lens.Cataract Surgery, in Miller S (ed): Clnical Ophthalmology. London, Wright; 1988:282-291.

140. Karim AKA, Jacob TJC, Thompson GM: The human lens epithelium; Morphological and ultrastructural changes associated with steroid therapy. Exp Eye Res 1989;48:215-224.

141. Karim AKA, Thompson GM, Jacob TJC: Steroid aerosols and cataract formation. BMJ 1989;299:918

142. Kass MA, Johnson T: Corticosteroid-induced glaucoma, in Rich R, Shields MB, Krupin T (eds): The Gla u comas. St.Louis, C.V. Mosby Company; 1989:1161-1168.

143. Katsunuma T, Akasawa A, Iikura Y: Adrenal function of children with bronchial asthma treated with beclomethasone dipropionate. Ann Allergy 1992;69:529-532.

144. Kaye LD, Kalenak JW, Price RL, Cunningham R: Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus 1993;30:142-144.

145. Kayes J, Becker B: The human trabecular meshwork in corticosteroid-induced glaucoma. Trans Am Op h thalmol Soc 1969;67:9-54.

146. Kewley GD: Possible association between beclomethasone diproprionate aerosol and cataracts. Aust Paed i atr J 1980;16:117-118.

147. Kinoshita JH: Mechanisms initiating cataract formation. Proctor lecture. Invest Ophthalmol 1974;13:713-724.

148. Kitazawa Y: Increased intraocular pressure induced by corticosteroids. Am J Ophthalmol 1976;82:492-495.

149. Kitazawa Y, Horie T: The prognosis of corticosteroid-responsive individuals. Arch Ophthalmol 1981;99:819-823.

150. Kitazawa Y, Horie T, Aoki S, Suzuki M, Nishioka K: Untreated ocular hypertension. A long-term prospective study. Arch Ophthalmol 1977;95:1180-1184.

151. Knepper PA, Breen M, Weinstein HG, Black LJ: Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone. Exp Eye Res 1978;27:567

152. Knepper PA, Collins JA, Federick R: Effect of dexamethasone, progesterone and testosterone on IOP and GAGs in the rabbit eye. Invest Ophthalmol Vis Sci 1985;26:1093-1100.

153. Kobayashi Y, Akaishi K, Nishio T, Kimura Y, Nagata M: Posterior subcapsular cataract in nephrotic children receiving steroid therapy. Am J Dis Child 1974;128:671-673.

154. Koch HR, Hillenblink M, Liappis N: Über den Einfluss einer Hydrocortisonbehandlung auf die Entwicklung von diabetischen Linsentrübungen bei Ratten. Albrecht v Graefes Arch klin exp Ophthal 1976;200:211-222.

155. Kramer MS: Clinical Epidemiology and Biostatistics. A Primer for Clinical Investigators and Decision-Makers, Heidelberg, Springer-Verlag; 1988

156. Kreienbrock L, Schach S: Epidemiologische Methoden, Stuttgart, Gustav Fischer; 1995

157. La Vecchia C, Negri E, D'Avanzo B, Boyle P, Franceschi S: Medical history and primary liver cancer. Canc Res 1990;50:6274-6277.

158. Laval J, Collier R: Elevation of intraocular pressure due to hormonal steroid therapy in uveitis. Am J Op h thalmol 1955;39:175-182.

159. LaVecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P: A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950-953.

160. Law CM, Marchant JL, Honour JW, Preece MA, Warner JO: Nocturnal adrenal suppression in asthmatic children taking inhaled beclomethasone dipropionate. Lancet 1986;1:942-944.

161. Lawson DH, Gray JMB, McKillop C, Clarke J, Lee FD, Patrick RS: Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986;234:945-955.

162. Lee PF: The influence of systemic steroid therapy on the intraocular pressure. Am J Ophthalmol 1958;46:328-331.

163. Leibowitz HM, Krueger DE, Maunder LR, et al: The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24:335-610.

164. Leiner S: Inhaled corticosteroids and the risk of cataract. New Engl J Med 1997;337:1554

165. Leske MC: The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983;118:166-191.

166. Leske MC, Sperduto RD: The epidemiology of senile cataracts: a review. Am J Epidemiol 1983;118:152-165.

167. Leufkens HG, Urquhart J: Automated record linkage and other approaches to pharmacoepidemiology in the Netherlands, in Strom BL (ed): Pharmacoepidemiology. Chichester, John Wiley and Sons; 1995:231-244.

168. Levene R, Wigdor A, Edelstein A, Baum J: Topical corticosteroid in normal patients and glaucoma suspects. Arch Ophthalmol 1967;77:593-597.

169. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO: The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contr a ception 1996;54:5-13.

170. Lidegaard O, Milsom I: Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996;53:135-139.

171. Limaye SR, Sasikala P, Leticia UT: Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol 1988;20:225-227.

172. Lipworth BJ: New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995;50:105-110.

173. Lipworth BJ, Clark DJ, McFarlane LC: Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax 1997;52:686-689.

174. Liu CS, Leonard TJ, Brown NA: The Lens Opacities Case-Control Study. Arch Ophthalmol 1991;109:1635-1636.

175. Livingston PM, Carson CA, Taylor HR: The epidemiology of cataract: A review of the literature. Ophtha l mic Epidemiology 1995;2:151-164.

176. Long WF: A case of elevated intraocular pressure associated with systemic steroid therapy. Am J Optom &Physiol Optics 1977;54:248-252.

177. Lou MF, Dickerson JEJ, Garadi R, York BMJ: Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res 1988;46:517-530.

178. Mabry RL: Corticosteroids in the management of upper respiratory allergy: the emerging role of steroid nasal sprays. Otolaryngol Head Neck Surg 1992;107:855-860.

179. MacDonald TM, McDevitt DG: The Tayside Medicines Monitoring Unit (MEMO), in Strom BL (ed): Pharmacoepidemiology. Chichester, John Wiley and Sons; 1995:245-255.

180. MacKenzie C: Effects of inhaled corticosteroids on growth. J Allergy Clin Immunol 1998;101 (suppl.):S451-S455.

181. Maclure M: The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;113:144-153.

182. MacMahon B, Trichopoulos D: Epidemiology. Principles and Methods, Boston, Little, Brown & Company; 1996

183. Majure M, Mroueh S, Spock A: Risk factors for the development of posterior subcapsular cataracts in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis treated with corticosteroids. Pediatric Pulmonol 1989;6:260-262.

184. Manabe S, Bucala R, Cerami A: Non-enzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest 1984;74:1803-1810.

185. Mason RP, Kosoko O, Wilson MR, et al: National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Part I. Prevalence findings. Ophthalmology 1989;96:1363-1368.

186. Matsumoto Y, Johnson DH: Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ. Invest Ophthalmol Vis Sci 1997;38:1902-1907.

187. Matthys H: Asthmatherapie mit topisch wirksamen Steroiden. Internist 1995;36:1005-1009.

188. Mayman CI, Miller D, Tijerina ML: In vitro production of steroid cataract in bovine lens. II. Measurement of sodium-potassium adenosine triphosphatase activity. Acta Ophthalmologica 1979;57:1107-1116.

189. McCowan C, Neville RG, Thomas GE, Crombie IK, Clark RA, Ricketts IW, Cairns AY, Warner FC, Greene SA, White E: Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. BMJ 1998;316:668-672.

190. Melchor R, Biddiscome MF, Mak VHF, Short MD, Spiro SG: Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstructions. Thorax 1993;48:506-511.

191. Miettinen OS: Theoretical Epidemiology: Principles of Occurrence Research in Medicine, New York, John Wiley & Sons; 1985

192. Miettinen OS: The 'case-control' study: valid selection of subjects. J Chron Dis 1985;38:543-548.

193. Miettinen OS, Caro JJ: Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1989;42:325-331.

194. Miller D, Peczon JD, Whitworth CG: Corticosteroids and functions in the anterior segment of the eye. Am J Ophthalmol 1965;59:31-34.

195. Miller E, Blatman B, Einarson TR: A survey of population-based drug databases in Canada. Can Med Assoc J 1996;154:1855-1864.

196. Mindel JS, Tavitian HO, Smith H, Walker EC: Comparative ocular pressure elevations by medrysone, fluorometholone and dexamethasone. Arch Ophthalmol 1980;98:1577-1578.

197. Mishima N, Nishida T, Otari T: Dexamethasone inhibition of phagocytosis by corneal keratocytes in culture. Arch Ophthalmol 1988;106:978-980.

198. Mitchell AA: Special Considerations in Studies of Drug-induced Birth Defects, in Strom BL (ed): Pharm a coepidemiology. New York, John Wiley & Sons; 1994:595-608.

199. Munoz B, Tajchman U, Bochow T, West S: Alcohol use and risk of posterior subcapsular opacities. Arch Ophthalmol 1993;111:110-112.

200. Müller-Breitenkamp U, Ohrloff C, Hockwin O: Aspekte zur Physiologie, Pathologie und Epidemiologie der Katarakt. Ophthalmologe 1992;89:257-267.

201. Nassif E, Weinberger M, Sherman B, Brown K: Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 1987;80:518-529.

202. National Institutes of Health: International Consensus Report on Diagnosis and Treatment of Asthma. Nat i onal Heart, Lung and Blood Institute 1992;pub no 92-3091:

203. Neumann F, Schenck B, Schleusener H, Schweikert HU: Endokrinpharmakologie. Pharmakotherapie mit Hormonen, in Forth W, Henschler D, Rummel W, Starke K (eds): Allgemeine und spezielle Pharmakologie und Toxikologie. Heidelberg, Spektrum Akademischer Verlag; 1996:581-637.

204. Nguyen TD, Huang W, Bloom E, Polansky JR: Glucocorticoid (GC) effects on HTM cells: Molecular biology approaches, in Lütjen-Drecoll E, Rohen JW (eds): Basic Aspects of Glaucoma Research III. Stuttgart, Schattauer; 1993:331-343.

205. Nicolaizik WH, Marchant JL, Preece MA, Warner JO: Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am J Respir Crit Care Med 1994;150:624-628.

206. Nikolaizik WH, Marchant JL, Preece MA, Warner JO: Nocturnal cortisol secretion in healthy adults before and after inhalation of budesonide. Am J Respir Crit Care Med 1996;153:97-101.

207. Ninan TK, Reid IW, Carter PE, Smail PJ, Russel G: Effects of high doses of inhaled corticosteroids on adrenal function in children with severe persistent asthma. Thorax 1993;48:599-602.

208. Nishigori H, Hayashi R, Lee JW, Iwatsuru M: Effect of MPG on glucocorticoid-induced cataract formation in developing chick embryo. Invest Ophthalmol Vis Sci 1984;25:1051-1055.

209. Opatowsky I, Feldman RM, Gross R, Feldman ST: Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995;102:177-179.

210. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS: Flunisolide: a review of its pharmacological properties and therapeutic efficay in rhinitis. Drugs 1980;19:397-411.

211. Paterson GD, Owen R: Further studies on systemic steroids, in Paterson G, Miller SJH, Paterson GD (eds): Drug mechanisms in glaucoma. London, J.&A. Churchill LTD; 1966:249-253.

212. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.

213. Pedersen S, Fuglsang G: Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J 1988;1:433-435.

214. Pedersen S, Steffensen G, Ohlsson SV: The influence of orally deposited budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol 1993;36:211-214.

215. Platt R: Harvard Community Health Plan, in Strom BL (ed): Pharmacoepidemiology. Chichester, John Wiley and Sons; 1995:277-287.

216. Polansky JR: HTM cell culture model for steroid effects on intraocular pressure: Overview, in Lütjen-Drecoll E, Rohen JW (eds): Basic Aspects of Glaucoma Research III. Stuttgart, Schattauer; 1993:307-318.

217. Polansky JR, Fauss DJ, Chen P, Chen H, Lütjen-Drecoll E, Johnson D, Kurtz RM, Ma ZD, Bloom E, Nguyen TD: Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 1997;211:126-139.

218. Polansky JR, Fauss DJ, Nguyen TD: Ophthalmic corticosteroids and steroid glaucoma mechanisms. Ophthalmol Clin North Am 1995;8:215-228.

219. Porter R, Crombie AL, Gardner PS, Uldall RP: Incidence of ocular complications in patients undergoing renal transplantation. BMJ 1972;3:133-136.

220. Prahl P: Adrenocortical suppression following treatment with beclomethasone and budesonide. Clin Exp Allergy 1991;21:145-146.

221. Pratt WB: The role of heat schock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 1993;268:21455-21458.

222. Putney LK, Brandt JD, O'Donnell E: Effects of dexamethasone on sodium-potassium-chloride cotransport in trabecular meshwork cells. Invest Ophthalmol Vis Sci 1997;38:1229-1240.

223. Quigley HA: Open-angle glaucoma. N Engl J Med 1993;328:1097-1106.

224. Ramsell TG, Trillwood W, Draper G: Effects of prednisolone eye drops. A trial of the effects of prednisolone phosphate eye drops on the intra-ocular pressure of normal volunteers. Br J Ophthalmol 1967;51:398-402.

225. Reddy VN, Giblin FJ: Metabolism and function of glutathione in the lens. Ciba Found Symp 1984;105:65-87.

226. Renfro L, Snow JS: Ocular effects of topical and systemic steroids. Dermatologic Clinics 1992;10:505-512.

227. Rohen JW, Linner E, Witmer R: Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res 1973;17:19-31.

228. Roll P, Benedikt O: Elektronenoptische Untersuchung des Trabekelwerkes bei einem Kortikosteroidglaukom. Klin Monatsbl Augenheilkd 1979;174:421-428.

229. Rooklin AR, Lampert SI, Jaeger EA, McGeady SJ, Mansmann HC: Posterior subcapsular cataracts in steroid-requiring asthmatic children. J Allergy Clin Immunol 1979;63:383-386.

230. Sackett DL: Bias in analytic research. J Chron Dis 1979;32:51-63.

231. Samples JR, Alexander JP, Acott TS: Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci 1993;34:3386-3395.

232. Schlötzer-Schrehardt U, Naumann GOH: Linse, in Naumann GOH (ed): Pathologie des Auges. Berlin, Springer; 1997:845-954.

233. Schwab IR, Armstrong MA, Friedman GD, Wong IG, Carpentieri AC, Dawson CR: Cataract extraction. Risk factors in a health maintenance organization population under 60 years of age. Arch Ophthalmol 1988;106:1062-1065.

234. Schwartz JT, Reuling FH, Feinleib M, Garrison RJ, Collie DJ: Twin heritability study of the effect of corticosteroids on intraocular pressure. Journal of Medical Genetics 1972;9:137-143.

235. Schwartz JT, Reuling FH, Feinleib M, Garrison RJ, Collie DJ: Twin study on ocular pressure after topical dexamethasone. 1. Frequency distribution of pressure response. Am J Ophthalmol 1973;76:126-136.

236. Schwartz JT, Reuling FH, Feinleib M, Garrison RJ, Collie DJ: Twin study on ocular pressure following topically applied dexamethasone. II. Inheritance of variation in pressure response. Arch Ophthalmol 1973;90:281-286.

237. Schwartz JT, Reuling FH, Jr., Feinleib M, Garrison RJ, Collie DJ: Twin heritability study of the corticosteroid response. Transactions - American Academy of Ophthalmology & Otolaryngology 1973;77:OP126-36.

238. Selroos O, Hulme M: Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered-dose inhaler and dry powder inhaler. Thorax 1991;46:891-894.

239. Shields MB: Glaucomas associated with ocular inflammation, in Shields MB (ed): Textbook of Glaucoma. Baltimore, Williams&Wilkins; 1992:356-373.

240. Shirato S, Bloom E, Polansky J, Alvarado J, Stilwell L: Phagocytotic properties of confluent cultured human trabecular meshwork cells (abstract). Invest Ophthalmol Vis Sci 1988;29 (suppl.):125

241. Sift R, Van Staa T, Abenhaim L, Ebner D: A study of the longitudinal utilization and switching-patterns of non-steroidal anti-inflammatory drugs using a pharmacy based approach. Pharmacoepidemiol Drug Saf 1997;6:263-268.

242. Simons FER, Persaud MP, Gillespie CA, Cheang M, Shuckett EP: Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993;342:776-778.

243. Simons FER, Simons KJ: Optimum pharmacological management of chronic rhinitis. Drugs 1989;38:313-331.

244. Skalka HW, Prchal JT: Effect of corticosteroids on cataract formation. Arch Ophthalmol 1980;98:1773-1777.

245. Skuta GL, Morgan RK: Corticosteroid-induced glaucoma, in Ritch R, Shields MB, Krupin T (eds): The Glaucomas. St. Louis, Mosby; 1996:1177-1188.

246. Smith CL: "Corticosteroid glaucoma" a summary and review of the literaure. Am J Med Sci 1966;252:239-244.

247. Smith MJ, Hodson ME: Effects of long-term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax 1983;38:676-681.

248. Snyder RW, Stamer WD, Kramer TR, Seftor REB: Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res 1993;57:461-468.

249. Sommer A, Tielsch JM, Katz J, et al: Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol 1991;109:1090-1095.

250. Sorva RA, Turpeinen MT: Asthma, glucocorticoids and growth. Ann Med 1994;26:309-314.

251. Sossie N, Hajek A, Palmberg P: Dexamethasone phosphate causes increased accumulation of hyaluronic acid in the cell layer of cultured human trabecular endothelial cells. Invest Ophthalmol Vis Sci 1982;22:192

252. Southren AL, Dominguez MO, Gordon GG, Wenk EJ, Hernandez MR, Dunn MW, Weinstein BI: Nuclear translocation of the cytoplasmic glucocorticoid receptor in the iris-ciliary body and adjacent corneoscleral tissue of the rabbit following topical administration of various glucocorticoids. Invest Ophthalmol Vis Sci 1983;24:147-152.

253. Southren AL, Gordon GG, l'Hommedieu D, Ravikumar S, Dunn MW, Weinstein BI: 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma. Invest Ophthalmol Vis Sci 1985;26:393-395.

254. Southren AL, Gordon GG, Yeh HS, Dunn MW, Weinstein BI: Receptors for glucocorticoids in the lens epithelium of the calf. Science 1978;200:1177-1178.

255. Southren AL, Gordon GG, Yeh HS, Dunn MW, Weinstein BI: Nuclear translocation of the cytoplasmic glucocorticoid receptor in the iris-ciliary body of the rabbit. Invest Ophthalmol Vis Sci 1979;18:517-521.

256. Spaeth GL, Rodrigues MM, Weinreb S: Steroid induced glaucoma: A. Persistent elevation of intraocular pressure. B. Histopathological aspects. Trans Amer Ophthalmol Soc 1977;75:353-381.

257. Spaeth GL, von Sallmann L: Corticosteroids and cataracts. International Ophthalmology Clinics 1966;6:915-928.

258. Spiers F: A case of irreversible steroid-induced rise in intraocular pressure. Acta Ophthalmol 1965;43:419-422.

259. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-506.

260. Sponsel WE, Rapoza PA: Posterior subcapsular cataract associated with indapamide therapy. Arch Ophthalmol 1992;110:454

261. Springer C, Avital A, Maayan C, Rosler A, Godfrey S: Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child 1997;62:815-819.

262. Starka L, Obenberger J: Steroids and intraocular pressure. J Steroid Biochem 1976;7:979

263. Steely HT, Browder SL, Julian MB, Miggans ST, Wilson KL, Clark AF: The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1992;33:2242-2250.

264. Stern JJ: Acute glaucoma during cortisone therapy. Am J Ophthalmol 1953;36:389-390.

265. Strand LM, Downey W: Health databases in Saskatchewan, in Strom BL (ed): Pharmacoepidemiology. Chichester, John Wiley and Sons; 1995:217-229.

266. Strom BL: Sample size considerations for pharmacoepidemiology studies, in Strom BL (ed): Pharmacoep i demiology. Chichester, John Wiley & Sons; 1994:29-38.

267. Strom BL: Pharmacoepidemiology, Chichester, Wiley; 1994:

268. Strom BL, Tugwell P: Pharmacoepidemiology: current status, prospects, and problems. Ann Intern Med 1990;113:179-181.

269. Suissa S: The case-time-control design. Epidemiology 1995;6:248-253.

270. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L: First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:

271. Szmyd L, Schwartz B: Association of systemic hypertension and diabetes mellitus with cataract extraction. Ophthalmology 1989;96:1248-1252.

272. Tamblyn R, Lavoie G, Petrella L, Monette J: The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.

273. Tavani A, Negri E, La Vecchia C: Selected diseases and risk of cataract in women. A case-control study from Northern Italy. Ann Epidemiol 1995;5:234-238.

274. Tavani A, Negri E, La Vecchia C: Food and nutrient intake and risk of cataract. Ann Epidemiol 1996;6:41-46.

275. Thorsson L, Edsbäcker S, Conradsen TB: Lung deposition of budesonide from Turbohaler is twice that from a pressurized metered-dose inhaler p-MDI. Eur Resp J 1994;7:1839-1844.

276. Tinkelman DG, Reed CE, Nelson HS, Offord KP: Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77.

277. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD: Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996;348:27-29.

278. Toogood JH: Side effects of inhaled corticosteroids. J Allergy Clin Immunol 1998;102:705-713.

279. Toogood JH, Jennings B, Hodsman AB, Baskerville J, Fraher LJ: Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol 1991;88:572-580.

280. Toogood JH, Markov AE, Baskerville J, Dyson C: Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol 1993;91:571-579.

281. Tripathi RC, Kirschner BS, Kipp M, Tripathi BJ, Slotwiner D, Borisuth NS, Karrison T, Ernest JT: Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroe n terology 1992;102:1957-1961.

282. Urban RC, Jr., Cotlier E: Corticosteroid-induced cataracts. Surv Ophthalmol 1986;31:102-110.

283. van Heyningen R: The human lens. I. A comparison of cataracts extracted in Oxford (England) and Shikarpur (W Pakistan). Exp Eye Res 1972;13:136-147.

284. van Heyningen R, Harding JJ: Do aspirin-like analgesics protect against cataract? A case-control study. Lancet 1986;1:1111-1113.

285. van Heyningen R, Harding JJ: A case-control study of cataract in Oxfordshire: some risk factors. Br J Op h thalmol 1988;72:804-808.

286. Van Staa T, Abenhaim L: Utilization dynamics and risk comparisons in studies that use prescription information. Pharmacoepidemiol Drug Saf 1994;3:191-197.

287. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM: Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1998;102:191-197.

288. Vie R: Glaucoma and amaurosis associated with long-term application of topical corticosteroids to the eyelids. Acta Derm Venereol 1980;60:541-542.

289. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I: Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993;329:1703-1708.

290. Volovitz B, Kauschansky A, Nussinovitch M, Harel L, Varsano I: Normal diurnal variation in serum cortisol concentration in asthmatic children treated with inhaled budesonide. J Allergy Clin Immunol 1995;96:874-878.

291. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS: Selection of controls in case-control studies: I. Principles. Am J Epidemiol 1992;135:1019-1028.

292. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS: Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol 1992;135:1029-1041.

293. Walker AM, Jick H, Gorman MR, Wallach RW: Steroids, diabetes, analgesics, and the risk of cataract. Lessons from the epidemiology of cataract extraction. J Clin Res Drug Dev 1988;2:227-232.

294. Weinreb RN, Bloom E, Baxter JD, Alvarado J, Lan N, O’Donnell J, Polansky JR: Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci 1981;21:403-407.

295. Weinreb RN, Polansky JR, Kramer SG, Baxter JD: Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci 1985;26:170-175.

296. Wenk EJ, Hernandez MR, Weinstein BI, Gordon GG, Dunn MW, Southren AL: Glucocorticoid receptor binding in bovine lens. Invest Ophthalmol Vis Sci 1982;22:599-605.

297. Werler MM, Pober BR, Nelson K, Holmes LB: Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989;129:415-421.

298. WHO: Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death Based on the Recommendations of the Ninth Revision Conference, 1975, Geneva, World Health Organization; 1977

299. Williamson J, Paterson RW, McGavin DD, Jasani MK, Boyle JA, Doig WM: Posterior subcapsular cataracts and glaucoma associated with long-term oral corticosteroid therapy. In patients with rheumatoid arthritis and related conditions. Br J Ophthalmol 1969;53:361-372.

300. Wilson AM, McFarlane LC, Lipworth BJ: Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol 1998;101:470-474.

301. Wilson DM, Martin JHS, Niall JF: Raised intraocular tension in renal transplant recipients. Med J Aust 1973;482-484.

302. Wilson K, McCartney MD, Miggans ST, Clark AF: Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Cur Eye Res 1993;12:783-793.

303. Wilson MR: Glaucoma in blacks: where do we go from here? JAMA 1989;261:281-282.

304. Wilson MR: Epidemiological features of glaucoma. Int Ophthalmol Clin 1990;30:153-160.

305. Wilson MR: Epidemiological features of glaucoma. Int Ophthalmol Clin 1990;30:153-160.

306. Wiseman LR, Benfield P: Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis. Drugs 1997;53:885-907.

307. Woodcock A: Effects of inhaled corticosteroids on bone density and metabolism. J Allergy Clin Immunol 1998;101:S456-S459.

308. Würthwein G, Rohdewald P: Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990;11:381-394.

309. Yiallouros PK, Milner AD, Conway E, Honour JW: Adrenal function and high dose inhaled corticosteroids for asthma. Arch Dis Child 1997;76:405-410.

310. Yola M, Lucien A: Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-737.

311. Yun AJ, Murphy CG, Polansky JR, Newsome DA, Alvarado JA: Proteins secreted by human trabecular cells. Glucocorticoids and other effects. Invest Ophthalmol Vis Sci 1989;30:2012-2022.

312. Zimmerman L: Demonstration of hyaluronidase-sensitive acid mucopolysaccaride. Am J Ophthalmol 1957;44:1

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: